ResMed Inc.
219.95USD
-1.1000 (-0.50%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $2.69▼ | $2.86 | 0 | 4 |
| Next quarter | $3.04▼ | $3.06 | 2 | 2 |
| Current year | $12.08▼ | $12.14 | 2 | 3 |
| Next year | $13.21▼ | $13.21 | 3 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $2.89 | $2.95 | +0.06 (+2.0%) |
| 2026-03-31 | $2.8 | $2.86 | +0.06 (+2.1%) |
| 2025-12-31 | $2.72 | $2.81 | +0.09 (+3.2%) |
| 2025-09-30 | $2.5 | $2.55 | +0.05 (+2.1%) |
221 ratings from 31 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Keybanc | Maintained | Overweight | $255 $267 | Aug 31, 2026 |
| Rothschild & Co | Initiated | Neutral | $230 | Aug 19, 2026 |
| RBC Capital | Maintained | Sector Perform | $234 $244 | Aug 7, 2026 |
| Piper Sandler | Maintained | Neutral | $233 $225 | Aug 7, 2026 |
| Keybanc | Maintained | Overweight | $260 $255 | Aug 7, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $225 $215 | Aug 7, 2026 |
| Mizuho | Maintained | Outperform | $235 $220 | Jul 15, 2026 |
| Citigroup | Downgraded from Buy | Neutral | $270 $235 | Jul 13, 2026 |
| Jefferies | Maintained | Hold | $240 $225 | Jul 10, 2026 |
| RBC Capital | Maintained | Outperform | $321 $276 | Jul 8, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $227 $225 | Jul 8, 2026 |
| Keybanc | Maintained | Overweight | $290 $266 | Jun 22, 2026 |
| Morgan Stanley | Downgraded from Overweight | Equal-Weight | $286 $230 | Jun 17, 2026 |
| Citigroup | Maintained | Buy | $340 $270 | Jun 15, 2026 |
| RBC Capital | Maintained | Outperform | $314 $321 | May 1, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $270 $227 | May 1, 2026 |
| Keybanc | Maintained | Overweight | $302 $290 | Apr 27, 2026 |
| Citigroup | Maintained | Buy | $345 $340 | Apr 9, 2026 |
| Citigroup | Maintained | Buy | $330 $345 | Feb 2, 2026 |
| RBC Capital | Maintained | Outperform | $311 $314 | Jan 30, 2026 |
| Piper Sandler | Maintained | Neutral | $270 $275 | Jan 30, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $265 $270 | Jan 30, 2026 |
| Stifel | Maintained | Hold | $260 $265 | Jan 30, 2026 |
| Stifel | Maintained | Hold | $270 $260 | Dec 18, 2025 |
| Baird | Downgraded from Outperform | Neutral | $300 $275 | Dec 16, 2025 |
147 filings from 18 insiders · 5 buy / 8 sell over 6m
Officers and directors of RMD, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| FARRELL PETER CDirector | Sell | 970 | $234.73 | $228k | Sep 2, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $205.69 | $1.03M | Aug 7, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | Aug 7, 2026 |
| FARRELL PETER CRAIGDirector | Sell | 8.0k | $225.00 | $1.80M | Aug 5, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $193.96 | $968k | Jun 8, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | Jun 8, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $207.82 | $1.04M | May 7, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | May 7, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $225.50 | $1.13M | Apr 7, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | Apr 7, 2026 |
| SANDERCOCK BRETTChief Financial Officer | Sell | 1.0k | $224.31 | $224k | Apr 1, 2026 |
| FARRELL PETER CRAIGDirector | Sell | 2.0k | $225.00 | $450k | Apr 1, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $251.03 | $1.25M | Mar 9, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | Mar 9, 2026 |
| FARRELL PETER CRAIGDirector | Sell | 2.0k | $260.22 | $520k | Mar 4, 2026 |
| SANDERCOCK BRETTChief Financial Officer | Sell | 1.0k | $254.30 | $254k | Mar 2, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Sell | 5.0k | $273.78 | $1.37M | Feb 9, 2026 |
| FARRELL MICHAEL JChief Executive Officer | Exercise | 5.0k | $146.34 | $730k | Feb 9, 2026 |
| FARRELL PETER CRAIGDirector | Sell | 2.0k | $251.31 | $503k | Feb 4, 2026 |
| RIDER MICHAEL JGeneral Counsel | Sell | 50 | $260.00 | $13k | Feb 4, 2026 |
No analyst notes on RMD yet.
Analyst Ratings
16 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 6 | 11 | 1 | 0 | Hold2.63 |
| 1 mo ago | 1 | 6 | 11 | 1 | 0 | Hold2.63 |
| 2 mo ago | 1 | 6 | 10 | 1 | 0 | Hold2.61 |
| 3 mo ago | 1 | 8 | 8 | 1 | 0 | Hold2.50 |